Cutaneous B-Cell Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission.
The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Secondary therapy for relapsed (disease returns after treatment) CBCL can include surgery, topical treatments, injected steroids, or radiation. Slow-growing CBCLs rarely transform into more aggressive types of lymphoma. For diseases that become widespread (systemic), regimens that may be used include:
- Rituximab (Rituxan), either alone or in combination with chemotherapy.
Treatments Under Investigation
Many treatments at various stages of drug development are currently being tested in clinical trials for relapsed or refractory CBCL, including:
- Lenalidomide (Revlimid)
- Bendamustine (Treanda)
- Rituximab (Rituxan)
Learn More
To learn more about CBCL, download the Cutaneous Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.
Additional Resources
To learn more about CBCL, download the Cutaneous B-Cell Lymphoma Fact Sheet.
Events
Ask the Doctor: Information for Relapsed/Refractory Patients
VirtualAsk the Doctor About Lymphoma is a virtual two-hour program that combines a comprehensive and […]
Pregunte al doctor sobre el linfoma
Pregúnte al Doctor sobre el linfoma es un programa virtual de dos horas que combina […]
Lymphoma Talk: Los Angeles
Westdrift Manhattan Beach 1400 Parkview Avenue, Manhattan Beach, CaliforniaLymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides […]